Early Short Stimulation Modified Natural Cycle IVF With GnRH Agonist Trigger and In Vitro Maturation in a Woman with Polycystic Ovary Syndrome: A Case Report

Dahan, Michael H.; Zhang, Lei; Chen, Hai Y.; Tan, Seang Lin

doi:10.1016/j.jogc.2016.02.002

Cited by 5 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some groups support the use of hCG in IVM cycles only when FSH priming was used; demonstrating the highest yield of MII stage oocytes for this specific combination [38]. Unsurprisingly, the use of GnRH agonist triggering has increased across ART practices, leading to a promising case report describing the successful use of GnRH agonist triggering in an IVM cycle [39]. This preliminary report reflects a possible advantage of GnRH-ag in IVM cycles, especially those performed for fertility preservation.…”

Section: Introductionmentioning

confidence: 99%

hCG Triggering in ART: An Evolutionary Concept

Klement

Shulman

2017

IJMS

View full text Add to dashboard Cite

Human chorionic gonadotropin (hCG) is no longer a single, omnipotent ovulation triggering option. Gonadotropin releasing hormone (GnRH) agonist, initially presented as a substitute for hCG, has led to a new era of administering GnRH agonist followed by hCG triggering. According to this new concept, GnRH agonist enables successful ovum maturation, while hCG supports the luteal phase and pregnancy until placental shift.

show abstract

Section: Introductionmentioning

confidence: 99%

hCG Triggering in ART: An Evolutionary Concept

Klement

Shulman

2017

IJMS

View full text Add to dashboard Cite

show abstract

“…GnRH-a administration was performed, to trigger ovulation, when the largest follicles were 10-12 mm in diameter. Many immature oocytes, which underwent maturation in vitro, were then harvested, fertilized, and subsequently developed into blastocysts that resulted in live births [13]. This interesting observation might have a great importance in follicular cytoplasmic maturation due to the FSH surge obtained after GnRH triggering.…”

Section: Human Chorionic Gonadotropin (Hcg)/gnrh-agonist Priming and mentioning

confidence: 93%

In Vitro Maturation and Fertilization of Oocytes: From Laboratory Bench to Clinical Practice

Ellenbogen¹,

Paz²,

Michaeli³

et al. 2020

Innovations in Assisted Reproduction Technology

View full text Add to dashboard Cite

Retrieval of immature oocytes from non-stimulated ovaries, followed by in vitro maturation (IVM), was initially proposed in order to avoid side effects of gonadotropin administration. The goal is to eradicate or significantly decrease the risk of ovarian hyperstimulation syndrome (OHSS) in patients with polycystic ovary syndrome (PCOS) and to reduce drug cost and burden of patients. This technology was also proposed for treatment of normal ovulatory women, fertility preservation, or infrequent conditions as failure of oocyte to mature or repeated development of poor-quality embryos. There is no downregulation, and only a small amount of hormones are injected if at all. In vitro maturation of the oocyte procedure obtained up to 35% clinical pregnancy rate in young women, compared with in vitro fertilization (IVF) in many programs. The obstetric and perinatal outcomes of IVM cycles are comparable with IVF/ICSI cycles; therefore it may gradually substitute IVF in certain cases, as the technique continues to develop and pregnancy rates continue to increase. IVM holds great promises as an alternative to assisted reproductive technologies and may be the procedure of choice not only for infertile patients but also for obtaining oocytes for donation or fertility preservation.

show abstract